Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Legend Biotech Corp ADR (NQ: LEGN )

50.13 -2.58 (-4.89%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 817,675
Open 53.11
Bid (Size) 50.06 (46)
Ask (Size) 50.08 (14)
Prev. Close 52.71
Today's Range 50.03 - 53.11
52wk Range 30.75 - 57.72
Shares Outstanding 308,456,852
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug
Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,... 
Via Talk Markets
Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI® (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
From Legend Biotech
Via Business Wire

Performance

YTD
+2.94%
+2.94%
1 Month
+2.94%
+2.94%
3 Month
+0.62%
+0.62%
6 Month
+11.15%
+11.15%
1 Year
+17.57%
+17.57%

More News

Read More
The Latest Analyst Ratings for Legend Biotech
Via Benzinga
Legend Biotech to Participate in the 41st Annual JP Morgan Healthcare Conference
From Legend Biotech
Via Business Wire
4 Analysts Have This to Say About Legend Biotech
Via Benzinga
Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China
From Legend Biotech
Via Business Wire
Gracell Biotech Stock Has Over 100% Upside On Next-Gen CAR-T Platforms, Analyst Claims
Via Benzinga
Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer
From Legend Biotech
Via Business Wire
Legend Biotech Announces Participation in Upcoming Investor Conferences
From Legend Biotech
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
Via Benzinga
Legend Biotech Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022
From Legend Biotech Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
Via Benzinga
Carnival, Amazon, Iamgold And Other Big Gainers From Tuesday
Via Benzinga
Why Legend Biotech's Shares Jumped 14.2% On Tuesday
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Via Benzinga
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
Via AB Newswire
Why Quoin Pharmaceuticals Shares Jumped By More Than 44%; Here Are 57 Biggest Movers From Yesterday
Via Benzinga
CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
Legend Biotech to Host 2022 R&D Day on Monday, October 3, 2022
From Legend Biotech Legend Biotech Corporation
Via Business Wire
No Early Relief for JW Therapeutics from Cancer Wonder Drug
Via Benzinga
Legend Biotech Stock Joins Elite Club Of Stocks With RS Ratings Over 90
Via Investor's Business Daily
Legend Biotech Announces Participation in Upcoming Investor Conferences
From Legend Biotech
Via Business Wire
NexImmune Pauses Developing Multiple Myeloma Hopeful, Citing Competition
Via Benzinga
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2022
From Legend Biotech Corporation
Via Business Wire
Legend Biotech Appoints Three New Directors and Elects New Chairman of the Board
From Legend Biotech
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.